OREANDA-NEWS. Protek Group (PRTK: RTS, MICEX), one of the major pharmaceutical companies in Russia, has announced its preliminary operating results for Q1-2014 according to the management accounts (unaudited).

In Q1-2014, the Production Segment's revenue decreased by 2.2% y-o-y to RUB 1,281 mln.

The Production Segment makes up 3.3% of the Group's total revenue.

In Q1-2014, revenue from proprietary brands decreased by 20% y-o-y to RUB 749 mln., compared to RUB 934 mln. in Q1-2013. Over Q1-2014, the product line embraced 63 proprietary brands, compared to 58 in Q1-2013.

Vadim Muzyaev, President of Protek Group: “Over the reporting period, the Protek Group has demonstrated consolidated revenue growth of 6.2%. The Retail Sales Segment was the top revenue gainer 14.4%. The slower expansion of consolidated revenue was driven by growing pricing competition in the Distribution Segment and smaller sales of AnviMax and Antigrippin in the Production Segment”.